Detalhe da pesquisa
1.
Genetic variants are major determinants of CSF antibody levels in multiple sclerosis.
Brain
; 138(Pt 3): 632-43, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25616667
2.
Prediction of antibody persistency from antibody titres to natalizumab.
Mult Scler
; 18(10): 1493-9, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22454098
3.
Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif™) using B cell receptor repertoire analysis.
J Neuroimmunol
; 370: 577932, 2022 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35853357
4.
Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study.
J Neuroimmunol
; 326: 19-27, 2019 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30447419
5.
Monocyte NOTCH2 expression predicts IFN-ß immunogenicity in multiple sclerosis patients.
JCI Insight
; 3(11)2018 06 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29875313
6.
Significantly increased fractions of transformed to total alpha2-macroglobulin concentrations in plasma from patients with multiple sclerosis.
Biochim Biophys Acta
; 1690(3): 203-7, 2004 Nov 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-15511627
7.
Oligoclonal band status in Scandinavian multiple sclerosis patients is associated with specific genetic risk alleles.
PLoS One
; 8(3): e58352, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23472185
8.
Stimulation of peripheral blood mononuclear cells with lipopolysaccharide induces expression of the plasma protein alpha2-macroglobulin.
Protein Expr Purif
; 27(2): 238-43, 2003 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-12597882